DIVERSE BIOTECH IS DEVELOPING LIFESAVING MEDICATIONS

for patients, healthcare professionals, and investors in therapeutic areas of greatest unmet need

Through Advancements In Natural Science, Medicine, And Genomics, we aim to improve the lives of patients who suffer from cancer and other debilitating diseases.

Diverse Biotech, Inc is an innovative biopharmaceutical research company committed to discovering and developing novel therapies from its proprietary conjugate drug synthesis Platform.


The company originated from oncologists adding cannabinoid therapy to standard of care treatment for cancer patients. The results were significant, unprecedented, and unpredicted.


Based on the initial results, Diverse Biotech has taken the science and technology to the next level and put an experienced Executive Leadership Team in place to take the company forward.

OUR SCIENCE

Human Endocannabinoid System

Conjugate Synthesis Platform

Human Endocannabinoid System

Vital Importance

Discovered in 1979, the
endocannabinoid system is a complex
system of tissue receptors which
interact with natural cannabinoids to
keep the human body in optimal health.

Once the endocannabinoid system
is activated, it sends signals to the
brain and tissues eliciting many effects
which take place through activation
of different receptor types (CB1, CB2,
TRPV1, & TRPV2).

Impacts many systems and organs in
the human body.

Conjugate Synthesis Platform

Basic Analogy

Conjugate Synthesis Platform

Targets the Brain

Specific Advantages of Conjugate Platform

Potential Step increase in efficacy

  • Rapid absorption and distribution
  • Increased lipophilicity (cross blood–brain barrier) – this is a big advantage & we should accentuate this with the cancer/conjugate type we select
  • Potential to lower dose of therapeutic agent

Potential Improved tolerability for patients

  • Decreased toxicity
  • Fewer side effects

Multiple Functionality

  • Across many drug families or classes in multiple disease states
  • Patent extension existing drugs
  • Somewhat ‘de-risking’ Drug Discovery with studied entities